Misplaced Pages

This is the current revision of this page, as edited by Citation bot (talk | contribs) at 18:13, 18 October 2024 (Added bibcode. | Use this bot. Report bugs. | Suggested by Spinixster | Category:Chemicals using indexlabels | #UCB_Category 243/831). The present address (URL) is a permanent link to this version.

Darunavir

Clinical data
Trade names	Prezista, others
Other names	TMC114, DRV, darunavir ethanolate
AHFS/Drugs.com	Monograph
MedlinePlus	a607042
License data	US DailyMed: Darunavir
Pregnancy category	AU: B2
Routes of administration	By mouth
Drug class	HIV protease inhibitor
ATC code	J05AE10 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	37% (without ritonavir), 82% (with ritonavir)
Protein binding	95%
Metabolism	Liver (CYP3A4)
Elimination half-life	15 hours (with ritonavir)
Excretion	Feces (80%), urine (14%)
Identifiers
IUPAC name oct-6-yl] N--3-hydroxy-1-phenyl- butan-2-yl] carbamate
CAS Number	206361-99-1
PubChem CID	213039
DrugBank	DB01264
ChemSpider	184733
UNII	YO603Y8113
KEGG	D03656 as salt: D06478
ChEBI	CHEBI:367163
ChEMBL	ChEMBL1323
NIAID ChemDB	073035
PDB ligand	017 (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID0046779
ECHA InfoCard	100.111.730
Chemical and physical data
Formula	C27H37N3O7S
Molar mass	547.67 g·mol
3D model (JSmol)	Interactive image
SMILES O=S(=O)(c1ccc(N)cc1)N(CC(C)C)C(O)(NC(=O)O2CO3OCC23)Cc4ccccc4
InChI InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1 Key:CJBJHOAVZSMMDJ-HEXNFIEUSA-N
(what is this?)  (verify)

Darunavir (DRV), sold under the brand name Prezista among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is generally recommended for use with other antiretrovirals. It is often used with low doses of ritonavir or cobicistat to increase darunavir levels. It may be used for prevention after a needlestick injury or other potential exposure. It is taken by mouth once to twice a day.

Common side effects include diarrhea, nausea, abdominal pain, headache, rash and vomiting. Severe side effects include allergic reactions, liver problems, and skin rashes such as toxic epidermal necrolysis. While poorly studied in pregnancy it appears to be safe for the baby. It is of the protease inhibitor (PI) class and works by blocking HIV protease.

Darunavir was approved by the US Food and Drug Administration (FDA) in June 2006. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.

It is available in the fixed-dose combination medication darunavir/cobicistat (Prezcobix, Rezolsta), and in the fixed-dose combination medication darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza).

Medical uses

Darunavir is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adults and children three years of age and older when co-administered with ritonavir, in combination with other antiretroviral agents.

Darunavir is an Office of AIDS Research Advisory Council (DHHS) recommended treatment option for adults and adolescents, regardless of whether they have received HIV treatment in the past. In a study of people that had never received HIV treatment, darunavir was as effective as lopinavir/ritonavir at 96 weeks with a once-daily dosing. It was approved by the FDA in October 2008, for people not previously treated for HIV. Darunavir does not cure HIV/AIDS.

Adverse effects

Darunavir is generally well tolerated by people. Rash is the most common side effect (7% of patients). Other common side effects are diarrhea (2.3%), headache (3.8%), abdominal pain (2.3%), constipation (2.3%), and vomiting (1.5%). Darunavir can also cause allergic reactions, and people allergic to ritonavir can also have a reaction to darunavir.

High blood sugar, diabetes or worsening of diabetes, muscle pain, tenderness or weakness, and increased bleeding in people with hemophilia have been reported in patients taking protease inhibitor medicines like darunavir. Changes in body fat have been seen in some patients taking medicines for HIV, including loss of fat from legs, arms and face, increased fat in the abdomen and other internal organs, breast enlargement, and fatty lumps on the back of the neck. The cause and long-term health effects of these conditions are not known.

Drug interactions

Darunavir may interact with medications commonly taken by people with HIV/AIDS such as other antiretrovirals, and antacids such as proton pump inhibitors and H2 receptor antagonists. St. John's wort may reduce the effectiveness of darunavir by increasing the breakdown of darunavir by the metabolic enzyme CYP3A.

Mechanism of action

Darunavir is a nonpeptidic inhibitor of protease (PR) that lodges itself in the active site of PR through a number of hydrogen bonds. It was developed to increase interactions with HIV-1 protease and to be more resistant against HIV-1 protease mutations. With a K_d (dissociation constant) of 4.5 x 10 M, darunavir has a much stronger interaction with PR and its dissociation constant is 1/100 to 1/1000 of other protease inhibitors. This strong interaction comes from increased hydrogen bonds between darunavir and the backbone of the PR active site (Figure 2). Darunavir's structure allows it to create more hydrogen bonds with the PR active site than most PIs that have been developed and approved by the FDA. Furthermore, the backbone of HIV-1 protease maintains its spatial conformation in the presence of mutations. Because darunavir interacts with this stable portion of the protease, the PR-PI interaction is less likely to be disrupted by a mutation.

Catalytic site

The chemical activity of the HIV-1 protease depends on two residues in the active site, Asp25 and Asp25', one from each copy of the homodimer. Darunavir interacts with these catalytic aspartates and the backbone of the active site through hydrogen bonds, specifically binding to residues Asp25, Asp25', Asp 29, Asp 30, Asp 30', and Gly 27 (Figure 3). This interaction prevents viral replication, as it competitively inhibits the viral polypeptides from gaining access to the active site and strongly binds to the enzymatic portions of this protein.

History

Darunavir was approved for use in the United States in June 2006 and for use in the European Union in February 2007.

The development of first-generation clinical inhibitors was founded on creating more protease-ligand interactions through hydrogen bonding and hydrophobic interactions. The first HIV protease inhibitor approved by the FDA was saquinavir, which was designed to target wild-type HIV-1 protease. However, this inhibitor is no longer effective due to resistance-causing mutations on the HIV-1 protease structure. The HIV genome has high plasticity, so has been able to become resistant to multiple HIV-1 protease inhibitors. Since saquinavir, the FDA has approved several PIs, including darunavir.

Society and culture

Economics

In the US and UK, healthcare costs were estimated to be lower with boosted darunavir than with investigator-selected control protease inhibitors in treatment-experienced patients.

References

1. ^ "Darunavir". The American Society of Health-System Pharmacists. Archived from the original on 10 November 2016. Retrieved 28 November 2016.
2. ^ "Darunavir (Prezista) Use During Pregnancy". Drugs.com. 23 October 2018. Archived from the original on 20 December 2016. Retrieved 21 April 2020.
3. "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 6 July 2023. Retrieved 30 March 2024.
4. ^ "Prezista- darunavir tablet, film coated Prezista- darunavir suspension". DailyMed. 6 June 2019. Archived from the original on 6 February 2019. Retrieved 21 April 2020.
5. ^ "Prezista EPAR". European Medicines Agency (EMA). Archived from the original on 25 June 2019. Retrieved 21 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
6. "Drug Approval Package: Prezista (Darumavir) NDA #021976". U.S. Food and Drug Administration (FDA). Archived from the original on 1 July 2016. Retrieved 26 May 2024.
7. MacArthur RD (April 2007). "Darunavir: promising initial results". Lancet. 369 (9568): 1143–1144. doi:10.1016/S0140-6736(07)60499-1. PMID 17416241. S2CID 31175809.
8. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
9. "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
10. "Prezcobix - darunavir ethanolate and cobicistat tablet, film coated". DailyMed. 2 January 2024. Archived from the original on 28 November 2023. Retrieved 26 May 2024.
11. "Darunavir / Cobicistat". Clinicalinfo. 27 November 2023. Archived from the original on 25 February 2024. Retrieved 26 May 2024.
12. "Symtuza - darunavir, cobicistat, emtricitabine, and tenofovir alafenamide tablet, film coated". DailyMed. 18 August 2023. Archived from the original on 9 July 2021. Retrieved 26 May 2024.
13. "Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenamide". Clinicalinfo. 20 June 2023. Archived from the original on 23 January 2024. Retrieved 26 May 2024.
14. "What's New: Adult and Adolescent ARV Guidelines". Clinicalinfo. 27 February 2024. Archived from the original on 26 November 2023. Retrieved 26 May 2024.
15. "What's New in the Guidelines? Adult and Adolescent ARV". AIDSinfo. 26 June 2018. Archived from the original on 14 September 2020. Retrieved 22 April 2023.
16. Antinori A, Lazzarin A, Uglietti A, Palma M, Mancusi D, Termini R (March 2018). "Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials". Scientific Reports. 8 (1): 5288. Bibcode:2018NatSR...8.5288A. doi:10.1038/s41598-018-23375-6. PMC 5869729. PMID 29588457.
17. "U.S. Food and Drug Administration (FDA) Approves Prezista Once-Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1". Drugs.com. 22 October 2008. Archived from the original on 23 September 2013. Retrieved 26 May 2024.
18. ^ Leonis G, Czyżnikowska Ż, Megariotis G, Reis H, Papadopoulos MG (June 2012). "Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps". Journal of Chemical Information and Modeling. 52 (6): 1542–1558. doi:10.1021/ci300014z. PMID 22587384.
19. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Béthune MP, Schiffer CA (November 2004). "Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor". Journal of Virology. 78 (21): 12012–12021. doi:10.1128/JVI.78.21.12012-12021.2004. PMC 523255. PMID 15479840. S2CID 828919.
20. ^ Lefebvre E, Schiffer CA (2008). "Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir". AIDS Reviews. 10 (3): 131–142. PMC 2699666. PMID 18820715.
21. Lascar RM, Benn P (2009). "Role of darunavir in the management of HIV infection". HIV/AIDS: Research and Palliative Care. 1: 31–39. doi:10.2147/hiv.s5397. PMC 3218677. PMID 22096377.
22. Li D, Zhang Y, Zhao RN, Fan S, Han JG (February 2014). "Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation". Journal of Molecular Modeling. 20 (2): 2122. doi:10.1007/s00894-014-2122-y. PMID 24526384. S2CID 23262721.
23. MacArthur RD (April 2007). "Darunavir: promising initial results". Lancet. 369 (9568): 1143–1144. doi:10.1016/S0140-6736(07)60499-1. PMID 17416241. S2CID 31175809.
24. "FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 13 November 2016. Retrieved 10 November 2016.
25. ^ "HIV/AIDS Historical Time Line 2000 - 2010". U.S. Food and Drug Administration (FDA). 5 January 2018. Archived from the original on 1 July 2019. Retrieved 21 April 2020.
26. "Drug Approval Package: Prezista (Darumavir) NDA #021976". U.S. Food and Drug Administration (FDA). 6 September 2006. Archived from the original on 1 July 2016. Retrieved 21 April 2020.
27. Liu F, Kovalevsky AY, Tie Y, Ghosh AK, Harrison RW, Weber IT (August 2008). "Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir". Journal of Molecular Biology. 381 (1): 102–115. doi:10.1016/j.jmb.2008.05.062. PMC 2754059. PMID 18597780.
28. Eron JJ (June 2000). "HIV-1 protease inhibitors". Clinical Infectious Diseases. 30 (Suppl 2): S160–S170. doi:10.1086/313853. PMID 10860901.
29. McKeage K, Perry CM, Keam SJ (2009). "Darunavir: a review of its use in the management of HIV infection in adults". Drugs. 69 (4): 477–503. doi:10.2165/00003495-200969040-00007. PMID 19323590. S2CID 195690027.

• Medicine
• Viruses

,

• Belgian inventions
• Carbamates
• Hepatotoxins
• Drugs developed by Johnson & Johnson
• Janssen Pharmaceutica
• HIV protease inhibitors
• Sulfonamides
• World Health Organization essential medicines
• Isobutyl compounds
• 4-Aminophenyl compounds